Abstract S47 Table 1.

Median treatment effects on PVR and CI

	PVR, dyn·sec/cm⁵ *(relative benefit^ to placebo expressed in %)**				CI, L/min/m²

	Macitentan 3mg	p-value	Macitentan 10mg	p-value	Macitentan 3mg	p-value	Macitentan 10mg	p-value

All	-28.7 (-32.2,-19.2)	<0.0001	-37.4 (-46.3,-26.6)	<0.0001	0.5 (0.3,0.8)	<0.0001	0.6 (0.4,0.9)	<0.0001
Treatment Naïve	-19.9 (-34.2,0.8)	0.06	-40.3 (-52.0,-22.3)	0.0002	0.4 (0.1,0.8)	0.01	0.6 (0.2,1.0)	0.004
Treated	-34.4 (-45.6,-22.3)	<0.0001	-33.3 (-45.6,-20.7)	0.0001	0.6 (0.4,1.0)	<0.0001	0.6 (0.2,1.0)	0.005
FC I/II	-35.2 (-49.2,-21.6)	<0.0001	-46.0 (-57.2,-28.8)	<0.0001	0.5 (0.2,0.9)	0.002	0.7 (0.2,1.1)	0.005
FC III/IV	-21.8 (-37.8,-9.2)	0.002	-29.0 (-43.8,-16.6)	0.0003	0.5 (0.3,0.9)	0.0001	0.6 (0.3,1.0)	0.001

Median (95% CL) placebo-corrected change from baseline and Wilcoxon test p-values;
↵* based on the log of Month 6/baseline values